Clalit Health Services, Southern District and the Department of Family Medicine and Siaal Research Center for Family Practice and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel .
Am J Ther. 2022 Jul 1;29(4):e400-e409. doi: 10.1097/MJT.0000000000001236.
Israel has a regulated system with clearly defined indications for treatment with medical cannabis.
The main question was whether family physicians in southern Israel face barriers/knowledge gaps in prescribing cannabis for medical indications. The secondary question was whether there was a difference between residents and specialists in family medicine.
A questionnaire-based cross-sectional study.
Attitudes of the participating physicians on the use of medical cannabis; comparison of attitudes of specialists in family medicine and residents on the use of medical cannabis.
One hundred and fifty-two family physicians participated in the study including 48 residents. More than 78% supported the use of medical cannabis and about 63% supported it's legalization. About 84% of the physicians believed that medical cannabis helped cancer patients and 82% believed it helped in the chronic pain. Only 28.3% believed that family physicians should recommend the use of medical cannabis. The physicians were well aware of the psychiatric (82%) and the neurological (78%) adverse effects of medical cannabis. Most (68%) were not willing to prescribe medical cannabis. No socio-demographic characteristic was associated with willingness to prescribe cannabis. About 95% of the physicians believed that the main barrier to recommending treatment was its potential for abuse, 66% percent-the danger that it would leak to the general public. About 60% of the specialists were not prepared to undergoing training in the prescription of medical cannabis compared with 31% of the residents ( P = 0.004).
Family physicians are concerned about recommending medical cannabis. It is encouraging that residents are motivated to undergo training to prescribe medical cannabis. There remain medical indications and adverse effects that family physicians are less aware of. Further studies should focus on effective ways to improve the level of physicians' knowledge on the issue.
以色列拥有一个监管体系,其中明确规定了医疗大麻的治疗适应证。
主要问题是以色列南部的家庭医生在为医疗适应证开具大麻处方时是否存在障碍/知识差距。次要问题是家庭医学的住院医师和专家之间是否存在差异。
基于问卷调查的横断面研究。
参与医生对使用医用大麻的态度;比较家庭医学专家和住院医师对使用医用大麻的态度。
共有 152 名家庭医生参与了这项研究,其中包括 48 名住院医师。超过 78%的医生支持使用医用大麻,约 63%的医生支持医用大麻合法化。约 84%的医生认为医用大麻有助于癌症患者,82%的医生认为医用大麻有助于慢性疼痛。只有 28.3%的医生认为家庭医生应该推荐使用医用大麻。医生们非常了解医用大麻的精神(82%)和神经(78%)不良影响。大多数(68%)的医生不愿意开医用大麻处方。没有社会人口学特征与开处方的意愿相关。约 95%的医生认为推荐治疗的主要障碍是其滥用的可能性,66%的医生认为它会泄露给公众。与 31%的住院医师相比,约 60%的专家不准备接受医用大麻处方培训(P=0.004)。
家庭医生对推荐医用大麻感到担忧。令人鼓舞的是,住院医师有动力接受培训以开具医用大麻处方。仍有一些适应证和不良反应是家庭医生不太了解的。进一步的研究应侧重于寻找有效方法来提高医生对该问题的认识水平。